YBX1 and acute myeloid leukemia: To validate the functional impact of YBX1 depletion in human AML in vivo, we performed a CRISPR-Cas9 mediated knockout as well as shRNA-mediated knockdown of YBX1 in MOLM13 cells and assessed leukemia dynamics after transplantation in humanized mice (Fig. 2K).